title: Comparison of oxidative stress markers in type 2 diabetes: basal bolus therapy versus twice daily premixed insulin analogs.
abstract: OBJECTIVE
  Several studies have shown that twice-daily injection of premixed insulin analog (MIX) therapy achieves glycemic control equivalent to that with basal-bolus (BB) therapy. However, glycemic fluctuations that lead to oxidative stress may be associated with the risk of diabetic complications. Therefore, in this study, we compared oxidative stress markers between MIX therapy and BB therapy.
  
  
  METHODS
  In this cross-sectional study, we recruited a total of 37 patients (17 patients in the BB group and 20 patients in the MIX group) and compared urinary 8-isoprostane and urinary 8-hydroxydeoxyguanosine (8-OHdG) levels.
  
  
  RESULTS
  There were no significant differences in urinary 8-isoprostane (BB vs MIX: 199+/-92 pg/mg Cr vs 266+/-107 pg/mg Cr) or urinary 8-OHdG (4.7+/-1.6 ng/mg Cr vs 5.4+/-1.9 ng/mg Cr, respectively). Conclusion These results suggest that MIX is equivalent to BB in terms of glycemic fluctuations and oxidative stress.
authors.affiliation: Diabetes Center, Kitasato Institute Hospital, Tokyo.
authors.forename: Masaki
authors.initials: M
authors.lastname: Sakamoto
authors.forename: Gaku
authors.initials: G
authors.lastname: Inoue
authors.forename: Kaoru
authors.initials: K
authors.lastname: Tsuyusaki
authors.forename: Kensuke
authors.initials: K
authors.lastname: Usui
authors.forename: Miwako
authors.initials: M
authors.lastname: Watanabe
authors.forename: Junichiro
authors.initials: J
authors.lastname: Irie
authors.forename: Koichiro
authors.initials: K
authors.lastname: Atsuda
authors.forename: Satoru
authors.initials: S
authors.lastname: Yamada
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000368:Aged; D015415:Biomarkers / Q000652:urine; D001786:Blood Glucose / Q000378:metabolism; D003430:Cross-Sectional Studies; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology* / Q000652:urine; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D007267:Injections; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; C075750:8-epi-prostaglandin F2alpha; D000080242:8-Hydroxy-2'-Deoxyguanosine; D015237:Dinoprost; D003849:Deoxyguanosine